Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Data updated
Papers
Trials
Research Footprint
Kayla Teopiz appears in 9 tracked papers (2021–2024), most studied alongside Ketamine, Esketamine and Psilocybin, across Depressive Disorders, Anxiety Disorders and Treatment-Resistant Depression (TRD).
Most-cited paper: Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis (169 citations).
Frequent co-authors: Jonathan Rosenblat, Roger McIntyre and Joseph Vincenzo.
Background & Research
Kayla M. Teopiz appears as an author on multiple publications focused on ketamine, esketamine, psilocybin, suicidality, sleep, and biomarkers in mood disorders. Her publication record suggests involvement in academic psychiatry research centered on treatment-resistant depression and related outcomes. I could not verify a definitive current faculty title from the available sources, so the affiliation is kept conservative.
Key Impact
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Collaboration Network
19 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Kayla Teopiz's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Kayla Teopiz is associated with.